V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Schrodinger Executive Compensation (FY25)

SDGR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Ramy Farid
Median of the other named officers
$2,011,376
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 23, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Schrodinger brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 23, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Schrodinger brief$1,500Get the executive brief
Velarion Member, one year
292 figures on this page: 287 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ramy Farid: $4,407,100 → $4,079,043 (7.4% lower)
Say-on-pay support: 94.4% → 98.3% (3.9 points higher)
CEO pay ratio: 26:1 → 23:1 (11.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Schrodinger's chief executive and what were they paid?
Total compensation for Ramy Farid, President and Chief Executive Officer, came to $4,079,043 in fiscal 2025. Compared with the $4,407,100 reported for fiscal 2024, Farid's total was 7.4% lower.
What was Schrodinger's say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.3% of votes cast for or against in favor at the meeting held June 23, 2026 for fiscal 2025.
Which companies are in Schrodinger's peer group?
The disclosed peer group includes 10x Genomics, Inc., Adaptive Biotechnologies Corp., Appian Corporation, Azenta, Inc. and Blueprint Medicines Corp., among others.
What is Schrodinger's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 23:1, against median employee compensation of $179,327.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ramy Farid
President and Chief Executive Officer
◇——◇◇—◇◇
Geoffrey Porges
Chief Financial Officer
◇◇—◇◇—◇◇
Karen Akinsanya
President, R&D Therapeutics
◇——◇◇—◇◇
Yvonne Tran
Chief Legal Officer
◇——◇◇—◇◇
Robert Abel
Chief Computational Scientist and Head of Modeling R&D
◇——◇◇—◇◇
Jenny Herman
Senior Vice President, Finance and Corporate Controller
◇——◇◇—◇◇
Joel Lebowitz
Former Chief Financial Officer
Departed during or after this year
◇—————◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ramy Farid
President and Chief Executive Officer
◇——◇◇—◇◇
Karen Akinsanya
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
◇——◇◇—◇◇
Geoffrey Porges
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ramy Farid
President and Chief Executive Officer
◇——◇◇—◇◇
Karen Akinsanya
President of R&D, Therapeutics
◇——◇◇—◇◇
Geoffrey Porges
Chief Financial Officer
◇——◇◇—◇◇
Robert Abel
Chief Scientific Officer, Platform
◇——◇◇—◇◇
Patrick Lorton
Chief Operating Officer, Software and Chief Technology Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ramy Farid
President and Chief Executive Officer
◇—◇◇◇—◇◇
Karen Akinsanya
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
◇—◇◇◇—◇◇
Geoffrey Porges
Former Executive Vice President, Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales and Marketing
◇◇◇◇◇—◇◇
Yvonne Tran
Executive Vice President, Chief Legal Officer and Chief People Officer
◇—◇◇◇—◇◇
Richie Jain
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Geoffrey PorgesOPTION◇——◇—◇◇
Mannix AklianOPTION◇——◇—◇◇
Ramy FaridOPTION◇——◇—◇◇
Ramy FaridOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Yvonne TranOption◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Karen AkinsanyaRSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Ramy FaridOption◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Richie JainRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Mannix AklianRSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Geoffrey Porges
Former Executive Vice President, Chief Financial Officer · Severance agreement · citing a 2025 filing
Severance cash amount◇
Change-in-control trigger◇
Equity acceleration on change in control◇
Benefits continuation◇
Karen Akinsanya
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales and Marketing · Severance agreement
Severance base◇
Change-in-control trigger◇
Equity acceleration on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Ramy Farid
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Yvonne Tran
Executive Vice President, Chief Legal Officer and Chief People Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard A. Friesner
◇◇◇——◇◇
Bridget van Kralingen
◇◇◇———◇
Michael Lynton
Board chair
◇◇◇———◇
Gary Sender
◇◇◇———◇
Jeffrey A. Chodakewitz
◇◇◇———◇
Gary Ginsberg
◇◇◇———◇
Rosana Kapeller-Libermann
◇◇◇———◇
Nancy A. Thornberry
◇◇◇———◇
Arun Oberoi
◇◇◇———◇
Ramy Farid served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • Adaptive Biotechnologies Corp. ADPT
  • Appian Corporation APPN
  • Azenta, Inc. AZTA
  • Blueprint Medicines Corp. BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Certara, Inc. CERT
  • CRISPR Therapeutics AG CRSP
  • Denali Therapeutics Inc. DNLI
  • Doximity, Inc. DOCS
  • Ginkgo Bioworks Holdings, Inc. DNA
  • Halozyme Therapeutics, Inc. HALO
  • Inspire Medical Systems, Inc. INSP
  • Ionis Pharmaceuticals IONS
  • Pacific Biosciences of California PACB
  • Quanterix Corporation QTRX
  • Recursion Pharmaceuticals, Inc. RXRX
  • Twist Bioscience Corp. TWST
  • Veracyte, Inc. VCYT
  • Veradigm Inc. MDRX
  • Yext, Inc. YEXT
  • Zuora Inc. ZUO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 23, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Ramy Farid (President and Chief Executive Officer), FY2025 total compensation $4,079,043 (base salary $730,000) [exec_comp, SEC accession 0001490978-26-000026, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Schrodinger files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Schrodinger disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Schrodinger sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Schrodinger's disclosed peer group is defensible, who names Schrodinger back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
292 figures on this page: 287 cited to the filing that reported them, 5 calculated from figures it prints.
287 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001490978-26-000049
  2. 0001490978-26-000045
    Exhibit
  3. 0001490978-26-000026
    Compensation Discussion and Analysis · EXECUTIVE AND DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Summary Compensation Table
  4. 0001490978-25-000082
  5. 0001490978-25-000047
    EXECUTIVE COMPENSATION TABLES
  6. 0001490978-24-000051
  7. 0001490978-24-000036
    Summary Compensation Table
  8. 0001490978-23-000064
  9. 0001490978-23-000039
    EXECUTIVE COMPENSATION TABLES
  10. 0001193125-22-175530
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001490978-25-000106
    EX-10.14
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Schrodinger executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SDGR (accessed 2026).
Short form: data: Velarion

The Schrodinger brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Schrodinger and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Schrodinger discloses

The companies named in SDGR's own disclosed peer group.

10x Genomics, Inc.Adaptive Biotechnologies Corp.Appian CorporationAzenta, Inc.Blueprint Medicines Corp.BridgeBio Pharma, Inc.Certara, Inc.CRISPR Therapeutics AGDenali Therapeutics Inc.Doximity, Inc.Ginkgo Bioworks Holdings, Inc.Halozyme Therapeutics, Inc.Inspire Medical Systems, Inc.Ionis PharmaceuticalsPacific Biosciences of CaliforniaQuanterix CorporationRecursion Pharmaceuticals, Inc.Twist Bioscience Corp.Veracyte, Inc.Veradigm Inc.Yext, Inc.Zuora Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy